under-perform price
upgrad in-lin pt forward
price-to-earnings tariff relief provid ep upsid
upgrad share in-lin rate follow
yesterday compani note receiv
exempt china rel tariff import us
happen background note custom tariff
commiss state council china exempt linac
tariff impos last year aug
recal var current guid contempl gross
impact mm major relat
aug tariff
net impact mm
contempl certain cost action benefit compani
updat number net basi think var ep hit
impact see benefit
given time exempt note
exempt retro-act
updat model reflect gm benefit
new ep estim prior estimate
upsid tariff relief off-set lower organ
top-line assumpt bundl relat uncertainti fx
upgrad outperform pt equat
forward price-to-earnings think fair ep upsid
tariff relief off-set bundling-rel uncertainti low visibl
china move exempt linac tariff rais question
whether view linac critic healthcar
infrastructur buildout henc potenti acceler quota
bundl relat uncertainti could continu weigh near
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
valuat methodolog base mix discount cash flow analysi rel valuat multipl
upsid risk halcyon contribut earlier expect result share gain revenu acceler robust
margin expans driven improv mix stronger expect ramp proton therapi medium term
articl articl
time dissemin septemb
analyst jon bristow vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
